NCT00453999已完成2 期
Phase II, Multicenter, Randomized, Double-Mask, Double-Dummy Study Comparing Efficacy and Safety of Intravenous Peramivir Once Daily Versus Oral Oseltamivir Twice Daily in Adults With Acute Serious or Potentially Life-Threatening Influenza
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 137
- 试验地点
- 83
- 主要终点
- Time to Clinical Stability (Kaplan-Meier Estimate)
研究概览
简要总结
This study has been designed as a randomized, double-blind, controlled, study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg) versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute serious or potentially life threatening influenza. Study treatments will be provided for up to 5 consecutive days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years of age, male or female
- •Able to provide informed consent, or for whom consent may be provided by guardian
- •Presence of fever at time of screening of ≥38.0°C (≥ 100.0°F) taken orally, or ≥38.5°C (≥101.2°F) taken rectally. This requirement is waived if the subject has (1) a history of fever within 24 hours prior to screening and administered any antipyretic(s) in the 24 hours prior to screening, or (2) has no history of documented fever as defined above, but reports a symptom of feverishness at some time during 48 hours prior to screening
- •Presence of at least 1 respiratory symptom (cough, sore throat, nasal congestion/symptoms) of any severity (mild, moderate, severe)
- •Presence of at least 1 constitutional symptom (headache, myalgia, feverishness, malaise, fatigue) of any severity (mild, moderate, severe)
- •Onset of illness no more than 72 hours before presentation. Time of onset of illness defined as either (1) the time when temperature (oral or rectal) was elevated (at least 1°C of elevation-oral temperature), OR (2) the time when the subject experienced the presence of at least 1 respiratory symptom AND the presence of at least 1 constitutional symptom
- •Presence of 1 or more of the following factors in a subject willing to be hospitalized for inpatient observation and treatment:
- •Age ≥60 years
- •Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy
- •History of congestive heart failure with or without medically significant recent change in cardiac status, but without signs or symptoms compatible with NYHA Class IV functional status
- •Presence of diabetes mellitus, clinically stable or unstable
- •Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value
- •Systolic blood pressure <90 mmHg
- •Severity of illness that, in the Investigator's judgment, justifies hospitalization of the subject for supportive care
- •Positive rapid antigen test (RAT) for influenza A and/or influenza B (using an approved test kit) or other test for influenza virus antigen performed in a clinical laboratory at the screening/enrollment evaluation
- •Females of childbearing potential must report one of the following:
- •Be surgically sterile or clinically post-menopausal
- •Have been sexually abstinent 4 weeks prior to date of screening evaluation and be willing to remain abstinent through 4 weeks after study-drug administration for all perimenopausal women or women of child-bearing potential
- •Use oral contraceptives or other form of hormonal birth control including hormonal vaginal rings or transdermal patches and have been using these for 3 months prior through 4 weeks after study-drug administration for all perimenopausal women or women of child-bearing potential
- •Use an intra-uterine device (IUD), or adequate barrier contraception (or double-barrier method such as condom or diaphragm with spermicidal gel or foam) as birth control 4 weeks prior to date of screening evaluation through 4 weeks after study drug administration for all perimenopausal women or women of child-bearing potential
排除标准
- •Immunized against influenza with live attenuated virus vaccine in the previous weeks
- •Treatment with any dose(s) of rimantadine, amantadine, zanamivir, or oseltamivir in the previous 7 days
- •Current clinical evidence of a recognized or suspected acute non-influenzal infectious illness with onset prior to Screening
- •Serum creatinine laboratory result at Screening >1.6 mg/dL or a result >25% above the upper limit of normal for the laboratory performing the test
- •History of clinically significant proteinuria (≥1000 mg/24 hrs)
- •History of moderate or severe renal impairment and/or previous clinical laboratory data indicating an estimated creatinine clearance <50 mL/min during the previous 12 months
- •Electrocardiogram (ECG) at Screening visit showing evidence of acute ischemia, or presence of a medically significant dysrhythmia
- •Presence of cardiac signs or symptoms compatible with NYHA Class III or Class IV functional status for congestive heart failure or angina (see NYHA Appendix V)
- •Presence of diagnosed COPD or other chronic lung condition requiring either continuous or intermittent oxygen therapy as an outpatient. Note: Subjects who are determined to require acute supplemental oxygen therapy at the time of Screening and/or at hospital admission may be enrolled, if exclusion criteria #13 or #14 are not applicable.
- •History of organ transplantation during the previous 12 months
- •Known HIV infection with most recent CD4+ T-cell count ≤350 cells/mL
- •History of diagnosis of any type of cancer (hematologic or solid tumor), that has required chemotherapy or radiation therapy in the previous 12 months, excluding non-melanomatous localized skin cancer
- •Presence of ongoing requirement for chronic mechanical ventilation, either via oral or nasotracheal intubation or via tracheostomy, or chronic or intermittent requirement for BiPAP (bilevel positive airway pressure) at screening. Note: Subjects who require intermittent CPAP treatment for sleep apnea (without oxygen supplementation) may be enrolled
- •Subjects who require acute mechanical ventilatory support of any type at the time of screening.
- •History of alcohol abuse or drug addiction during the previous 12 months
- •Participation in a clinical study of an experimental medication or other treatment during the previous 4 weeks
- •Previous treatment with intravenous or intramuscular peramivir
- •Women who are pregnant (positive serum or urine pregnancy test), who are attempting to become pregnant, or who are breast-feeding
- •Subjects who have been hospitalized due to a condition other than acute influenza and in whom influenza is diagnosed during hospitalization.
研究组 & 干预措施
Arm 1: Peramivir 200 mg
Experimental
Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
干预措施: Peramivir 200 mg (Drug)
Arm 2: Peramivir 400 mg
Experimental
Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
干预措施: Peramivir 400 mg (Drug)
Arm 3: Oseltamivir
Experimental
Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
干预措施: Oseltamivir (Drug)
结局指标
主要结局
Time to Clinical Stability (Kaplan-Meier Estimate)
时间窗: 14 days
Time to clinical stability was summarized overall and for individual clinical signs for each treatment group using the method of Kaplan Meier. Subjects who did not experience clinical stability were censored at the date of their last non-missing assessment during the study (whether this assessment occurred as an inpatient or as an outpatient).
次要结局
- Time to Resumption of Ability to Perform Usual Activities (Kaplan-Meier Estimate)(14 days)
- Change From Baseline in Scores of Symptoms of Influenza(Baseline, Days 2, 3, 4, 5, 10, and 14)
- Time to Hospital Discharge (Kaplan-Meier Estimate)(14 days)
- Incidence of Clinical Relapse of Influenza After Treatment (Number of Participants Experiencing Relapse During the Study)(14 days)
- Change in Amount of Influenza Virus in Nose and Throat (Influenza A and B Combined)(Baseline, and 12, 24, 36, 48, 72, and 96 hours)
研究者
研究点 (83)
Loading locations...
相似试验
已完成
2 期
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye DiseaseThyroid Eye DiseaseNCT06525506Innovent Biologics (Suzhou) Co. Ltd.38
已完成
2 期
QA108 Phase II Study in Subjects With Intermediate Age-Related Macular DegenerationIntermediate Age-Related Macular DegenerationNCT05562219Smilebiotek Zhuhai Limited120
已完成
2 期
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular EdemaDiabetic Macular EdemaNCT02348918Allegro Ophthalmics, LLC218
已完成
2 期
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLCNon Small Cell Lung CancerNCT05519865Chipscreen Biosciences, Ltd.118
已完成
2 期
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTelMacular Telangiectasia Type 2NCT01949324Neurotech Pharmaceuticals67